Could a common arthritis drug help skin issues in down syndrome?
NCT ID NCT04246372
First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 16 times
Summary
This study tested the safety and effectiveness of tofacitinib, a drug that blocks certain immune signals, for treating skin conditions like eczema and psoriasis in people with Down syndrome. 47 adolescents and adults took part. The goal was to see if the drug could improve these skin problems and measure its impact on immune markers and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Linda Crnic Institute for Down Syndrome
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.